Naltrexone oral
Alternative Names: Low-dose naltrexone (LDN) - Transparency Life Sciences; Nalorex; Nemexin; ReviaLatest Information Update: 28 Oct 2021
At a glance
- Originator DrugAbuse Sciences
 - Developer Transparency Life Sciences
 - Class Alcohols; Anti-inflammatories; Antineoplastics; Antivirals; Cyclic ethers; Cyclohexanes; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Furans; Irritable bowel syndrome therapies; Ketones; Morphinans; Naphthols; Non-opioid analgesics; Phenanthrenes; Phenols; Piperidines; Small molecules
 - Mechanism of Action Opioid receptor antagonists
 
- 
          
            
              Orphan Drug Status
              Yes - Opioid-related disorders
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Marketed Alcoholism; Opioid-related disorders
 - No development reported Crohn's disease
 
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Crohn's-disease in USA (PO)
 - 18 Dec 2012 Early research in Crohn's disease in USA (PO)
 - 01 Feb 2012 Early research in Inflammatory bowel disease in USA (PO)